Breaking News, Collaborations & Alliances

GSK, AFFiRiS Enter Alzheimer’s Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline Biologicals (a GSK unit) and AFFiRiS GmbH have entered a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programs that target beta-amyloid. GSK is acquiring exclusive rights to develop and commercialize two vaccine candidates currently in Phase I development that are based on AFFiRiS AFFiTOPE technology. GSK also has an exclusive option to develop and commercialize alternative Alzheimer’s vaccine candidates in precl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters